SCHEMBL7192308

SCHEMBL7192308

CCCCCCCCCC(=O)N(C(=O)CCCCCCCCC)C(CCCN)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.44
FFAR1 O14842 2/20 0.44
SLC6A5 Q9Y345 1/20 0.42
GRIK1 P39086 1/20 0.41
GRIK2 Q13002 1/20 0.41
GPR84 Q9NQS5 8/20 0.40
PPARG P37231 7/20 0.40
PPARD Q03181 7/20 0.40
PPARA Q07869 7/20 0.40
HDAC11 Q96DB2 5/20 0.40
TSHR P16473 4/20 0.40
PTPN1 P18031 3/20 0.40
ALDH1A1 P00352 2/20 0.40
TLR2 O60603 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
FABP4 P15090 2/20 0.40
SLC22A6 Q4U2R8 1/20 0.40
SLC22A8 Q8TCC7 1/20 0.40
MEN1 O00255 1/20 0.40
ESR1 P03372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9716626 1.00 FFAR4 (0.44) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL9716640 1.00 FFAR4 (0.44) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL9716766 1.00 FFAR4 (0.44) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL11835782 1.00 FFAR4 (0.44) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL9716761 1.00 FFAR4 (0.44) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL9716621 1.00 FFAR4 (0.44) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL9716667 1.00 FFAR4 (0.44) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL9716644 1.00 FFAR4 (0.44) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL7192321 0.98 FFAR4 (0.41) FFAR4FFAR1SLC6A5GRIK1GRIK2
SCHEMBL7192319 0.98 FFAR4 (0.41) FFAR4FFAR1SLC6A5GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030091520-A1 Use of at least one polar additive in a cosmetic composition comprising a liquid fatty phase structured by at least one molecular organogelator, to impart a thixotropic character to the composition L'OREAL (FR) 2003-05-15 US disclosed
EP-1264589-A1 Use of a polar additive in a cosmetic composition containing a structured liquid oil phase by at least one organogelator to give a thixotropic character L'OREAL (FR) 2002-12-11 EP disclosed
US-6214329-B1 PIGMENTED EMULSION OF NON-POLYMERIC GELLING AGENT SUCH AS N-ACYL AMINO ACIDS, ESTERS OR AMIDES, 12-HYDROXYSTEARIC ACID, ESTER, OR AMIDE, FATTY ESTERS OF POLYFUNCTIONAL ALCOHOL DIMERS, AND ALKYLAMIDES OF DI- OR TRI-CARBOXYLIC ACIDS REVLON CONSUMER PRODUCTS CORPORATION 2001-04-10 US disclosed
WO-2000074519-A2 MASCARA COMPOSITIONS AND METHODS FOR CURLING LASHES REVLON CONSUMER PRODUCTS CORPORATION (US) 2000-12-14 WO disclosed
EP-0178911-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1992-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030091520-A1 Use of at least one polar additive in a cosmetic composition comprising a liquid fatty phase structured by at least one molecular organogelator, to impart a thixotropic character to the composition PLIN3, CUTA, FABP4 FFAR4 256/4885FFAR1 310/4885SLC6A5 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.